MADISON, Wis., May 21, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that a District Court judge denied in part Geneoscopy’s (defendant) motion to dismiss a patent infringement lawsuit filed by Exact Sciences (plaintiff) in the United States District Court for the District of Delaware. This ruling paves the way for Exact Sciences to seek relief for Geneoscopy’s future infringement and false advertising.
There's been a notable change in appetite for Exact Sciences Corporation ( NASDAQ:EXAS ) shares in the week since its...
Comparative Analysis of Q1 Performance Against Analyst Projections